|Minimum Order Quantity||3 Bottle|
|Packaging Size||28 tablet|
|Application||for hapatitis c|
Product description:Velpanat Natco India Velpatasvir and Sofosbuvir Tablets Details
Dacikast 60mg (Daclatasvir) is an inhibitor of non-structural protein 5A (NS5A). Each film-coated tablet contains Daclatasvir Dihydrochloride equivalent to Daclatasvir 30 mg or 60mg. Empirical formula for Daclatasvir Dihydrochloride is C40H50N8 O6. 2HCl. Daclatasvir is white to yellow colour solid and freely soluble in water. The tablets include the following inactive ingredients: Anhydrous Lactose, Microcrystalline cellulose, Croscarmellose sodium, Colloidal silicon dioxide, Magnesium stearate, Opadry Orange
Mechanism of Action
Dasikast Tablets Daclatasvir 60mg is an inhibitor of nonstructural protein 5A (NS5A), a multifunctional protein that is an essential component of the HCV replication complex. Daclatasvir inhibits both viral RNA replication and virion assembly.
The pharmacokinetic properties of Dasikast (Daclatasvir) were evaluated in healthy adult subjects and in patients with chronic HCV. Following multiple oral doses of Daclatasvir 60 mg once daily in combination with peg interferon alfa and ribavirin in treatment naive patients with genotype 1 chronic HCV, the geometric mean (CV%) Daclatasvir Cmax was 1534 (58) ng/ml, AUC0-24h was 14122 (70) ng*h/ml, and Cmin was 232 (83) ng/ml.
INDICATIONS AND USAGE
Dacikast is indicated in combination with Sofosbuvir for the treatment of patient with chronic hepatitis C virus (HCV) genotype 3 infection.
DOSAGE AND ADMINISTRATION
Treatment with Dacikast should be initiated and monitored by a physician experienced in the management of chronic hepatitis C. The recommended dose of Dacikast is 60 mg once daily, to be taken orally with or without meals. Dacikast must be administered in combination with other medicinal products. The Package Inserts of the other medicinal products in the regimen should also be consulted before initiation of therapy with Dacikast. Recommended regimens and treatment duration are provided in Table 1
Hypersensitivity to the active substance or to any of the Excipients Co-administration with medicinal products that strongly induce cytochrome P450 3A4 (CYP3A4) and P-glycoprotein transporter (P-gp) and thus may lead to lower exposure and loss of efficacy of Daclatasvir. These active substances include but are not limited to phonation, carbamazepine, oxcarbazepine, phenobarbital, rifampicin, rifabutin, rifapentine, systemic dexamethasone, and the herbal product St John’s wort (Hypericum perforatum).
There is limited experience of accidental overdose of Daclatasvir in clinical trials. In phase 1 clinical trials, healthy subjects who received up to 100 mg once daily for up to 14 days or single doses up to 200 mg had no unexpected adverse reactions. There is no known antidote for overdose of Daclatasvir. Treatment of overdose with Daclatasvir should consist of general supportive measures, including monitoring of vital signs, and observation of the patient’s clinical status. Because Daclatasvir is highly protein bound (99%) and has a molecular weight >500, dialysis is unlikely to significantly reduce plasma concentrations of Daclatasvir
HOW SUPPLIED AND STORAGE
Dacikast 30 mg tablets are available in bottle pack of 28 tablets. Dacikast 60 mg tablets are available in bottle pack of 28 tablets. Store below 25°C
Abamune-L is taken with other antiretroviral medications to treat adults infected with HIV-1. A single pill is the equivalent of 300mg of lamivudine IP and 600mg of abacavir. At least one other anti-HIV medication must be co-administered with Abamune-L to effectively prevent HIV from progressing to AIDS.Dosing Administration
The recommended dose of Abamune-L for adults is one pill daily along with other antiretroviral medications. Abamune-L may be taken with or without food.Contraindications
Any patient who has hepatic impairment should not take Abamune-L. Anyone with a prior history of hypersensitive reaction to abacavir or any of the other ingredients in Abamune-L should also not take the drug. Do not take any abacavir containing products after experiencing a hypersensitive reaction.Side Effect:
Taking Abamune-L has been associated with the following side effects:
In rare incidences, cases of fatal hypersensitive reactions to abacavir, a core ingredient of Abamune-L, have been reported. Other side effects may occur. Let a doctor know immediately if you feel any changes in your well being when you begin taking Abamune-L.